Resultado da Busca
3 de abr. de 2024 · Explore a collection of articles and other resources on the Coronavirus (Covid-19) outbreak, including clinical reports, management guidelines, and commentary.
20 de ago. de 2021 · Download Full Issue. The Long COVID Conundrum. Adam W. Gaffney, MD, MPH. Published: August 20, 2021 DOI: https://doi.org/10.1016/j.amjmed.2021.07.037. The Long COVID Conundrum. Once the coronavirus disease 2019 (COVID-19) pandemic ebbs, attention will likely shift to the disease's long-term complications, dubbed “long COVID.”
- Adam W. Gaffney, Adam W. Gaffney
- 2021
22 de set. de 2021 · Vaccine Effectiveness. For the period of 0 to 9 days after receipt of the first dose, the vaccine effectiveness was 12.8% (95% confidence interval [CI], −9.4 to 30.5). Vaccine effectiveness at ...
- Tamara Pilishvili, Ryan Gierke, Katherine E Fleming-Dutra, Jennifer L Farrar, Nicholas M Mohr, David...
- 2021
2 de mar. de 2022 · In this study, we estimated vaccine effectiveness against symptomatic disease caused by the delta and omicron variants after two doses (primary immunization) of BNT162b2, mRNA-1273, or ChAdOx1 ...
A collection of the latest articles and resources on COVID-19, including ivermectin trials, historic Q&A's with former NIAID Director Anthony Fauci, and more. View all COVID-19. RESEARCH. Research Letter. Mortality in Patients Hospitalized for COVID-19 vs Influenza in Fall-Winter 2023-2024.
28 de set. de 2023 · Persistent coronavirus disease 2019 (covid-19) symptoms are increasingly well-reported in the literature. These persistent symptoms following acute infection, otherwise known as ‘long covid’, have affected people worldwide. Long covid is a heterogeneous disease with multimorbidities affecting several physiological systems.
2 de abr. de 2020 · Coverage of latest information on COVID-19 from across the medical literature and put into context for you by NEJM Journal Watch editors. Articles. Filter by Date. Apr 10, 2024. |. Infectious Diseases. Hospital Medicine. Monoclonal Antibody Receives Emergency Use Authorization for Preventing COVID-19 in High-Risk Patients. Daniel Kaul, MD.
